



## **GBT Announces Participation at the H.C. Wainwright Global Life Sciences Conference**

April 2, 2019

SOUTH SAN FRANCISCO, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019, at 10:10 a.m. British Summer Time.

The presentation will be webcast live from GBT's website at [www.gbt.com](http://www.gbt.com) in the [Investors](#) section. A replay of the webcast will be archived and available for replay for one month following the event.

### **About GBT**

GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing two therapies for the potential treatment of sickle cell disease, including its late-stage product candidate, voxelotor, as an oral, once-daily therapy. To learn more, please visit [www.gbt.com](http://www.gbt.com) and follow the company on Twitter @GBT\_news.

### **Contact Information:**

Myesha Lacy (investors)

GBT

650-351-4730

[investor@gbt.com](mailto:investor@gbt.com)

Stephanie Yao (media)

GBT

650-741-7730

[media@gbt.com](mailto:media@gbt.com)



Global Blood Therapeutics, Inc.